"Promotion Steering Committee" In Planning Stage, FDA Ad Division Head Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The group will include senior officials from the drug and biologics review centers and reps from the chief counsel's and commissioner's offices, CDER ad division director Abrams says. CDER has issued eight warning letters this year; omission of risk information and unproven claims are most common violations.